Abstract
Zoledronic acid, a third-generation bisphosphonate, is the monohydrate of 1-hydrox-2 ([H-imidazole-1-yl] ethylidene) bisphosphonic acid. Zoledronic acid is registered in over 80 countries throughout the world for tumor-induced hypercalcemia and for the prevention of skeletal-related events in patients with solid tumor metastases or multiple myeloma with bone lesions. Zoledronic acid currently has investigational status for the treatment of Paget’s disease of bone, osteoporosis and a number of other bone disorders. This review will focus on the potential future use of zoledronic acid, a potent and easily administered intravenous bisphosphonate, in Paget's disease of bone and osteoporosis – two disorders likely to be commonly treated by rheumatologists. Another potential utility, the suppression of osteoclast-mediated bone erosions in inflammatory arthritis, will be briefly mentioned.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
